Immuneering (IMRX) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vogenx is the larger company by market cap ($247.9 million vs $238.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | VOGX |
|---|---|---|
| Share price | $3.68 | $16.69 |
| Market cap | $238.09M | $247.93M |
| 1-day change | -4.66% | +3.28% |
| YTD return | -41.34% | — |
| 1-year return | -36.82% | — |
| 5-year return | -84.47% | — |
| EPS (TTM) | $-0.93 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.48 | $38.41 |
| 52-week low | $3.60 | $12.95 |
| Distance from 52-week high | -56.60% | -56.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +366.58% | +229.54% |
| Average volume | 694.54K | 188.79K |
| Shares outstanding | 64.70M | 14.86M |
| Employees | 57 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
IMRX vs VOGX FAQ
Which is bigger, Immuneering or Vogenx?
Vogenx (VOGX) is larger, with a market capitalization of $247.93M compared with $238.09M for Immuneering (IMRX).
Are Immuneering and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.